SDMHF News Alert Sartorius Stedim Bio (SDMHF) 166.2500 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sartorius Stedim Bio (SDMHF) 166.2500 $SDMHF

Research and Markets: Global Single-Use Bio-Processing Systems Market 2014-2018 With GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating
Business Wire - Thu Jul 17, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twp8ts/global_singleuse) has announced the addition of the "Global Single-use Bio-processing Systems Market 2014-2018 with GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating" report to their offering.

Global Single-use Bio-processing Systems Market 2014-2018 with GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating
M2 - Thu Jul 17, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dkzwqv/global_singleuse) has announced the addition of the "Global Single-use Bio-processing Systems Market 2014-2018 with GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating" report to their offering. The Global Single-use Bio-processing Systems market will grow at a CAGR of 38% to 2018 The report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. Owing to the growing potential of the Global Single-use Bio-processing Systems market, many bio-processing systems manufacturers collaborate to develop new platforms for the cultivation of cells or to develop new systems. For example, Sartorius's collaboration with Refine Technology LLC for the development of a robust platform for high-density cell cultivation. This platform will enable fast and easy connection of the alternating tangential flow system to Sartorius Stedim Biotech's field-proven single-use BIOSTAT bioreactors. Moreover, the partnership would enable the development of new designs of clinical analyzers and enable vendors to stay competitive in the market. This in turn could boost the growth of the Global Single-use Bio-processing Systems market. According to the report, the increasing demand for biopharmaceuticals is one of the major drivers in this market. The aging population in the US is expected to double and reach a total of 71 million by 2030. Cardiovascular diseases, Alzheimer's, and cancer are some of the most common diseases seen in the aged. Therefore, the steadily growing aging population increases the prevalence of these diseases, which in turn increases the demand for biopharmaceuticals. Further, the report states that the implementation of stringent regulations is one of the major challenges faced by the vendors in this market. Currently, the regulations for single-use bio-processing systems are not completely defined and documented, because the FDA has been quite liberal in not imposing more stringent regulations. However, the regulations are still uncertain owing to the limited usage of single-use bio-processing systems in commercial production. Key Vendors - GE Healthcare - Merck & Co Inc. - Sartorius Stedim Biotech SA - ThermoFisher Scientific Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Applications - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dk..._singleuse

Pharmaceutical Membrane Filtration Market by Technology, Application, Region - Trends & Forecast to 2018
M2 - Fri Mar 14, 4:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfm638/pharmaceutical) has announced the addition of the "Pharmaceutical Membrane Filtration Market by Technology, Application, Region - Trends & Forecast to 2018" report to their offering. Membrane filtration is a widely used separation technique in pharmaceutical and biotechnology industries. It finds extensive applications in the biopharmaceutical industry as biopharmaceutical products and their intermediates are susceptible to degradation due to heat and chemical treatment, and so are difficult to separate using other techniques. Membrane filtration has been used in pharmaceutical industry since 1935 and it is presently one of the most widely adopted separation techniques in this industry. The global pharmaceutical membrane filtration market is segmented on the basis of technology, application, and region. The technology segments included in the report are microfiltration, ultrafiltration, nanofiltration, reverse osmosis, and ion exchange; the application segments are cell separation, protein purification, sterilization, virus removal, and water management; while the geographic segments are North America, Europe, Asia-Pacific, and Rest of the World (RoW). The major factor driving the growth of this market is the growth of the global pharmaceutical industry. The adoption rate of membrane filtration in Europe and North America is very high. Further, increasing adoption rate in the Asia-Pacific segment and increasing demand for single use technology will further drive this market. Therefore, the pharmaceutical membrane filtration market is expected to witness a high growth in the forecast period. Membrane filtration is also used widely for protein purification in the pharmaceutical industry. Other important applications of this technology in the pharmaceutical industry are cell separation and water treatment. Microfiltration and ultrafiltration are the most widely used filtration technologies in the pharmaceutical industry. In 2013, Europe was the largest market for pharmaceutical membrane filtration. However, the North American market is expected to grow rapidly in the forecast period between 2013 and 2018 and is expected to be as large as that of Europe by 2018. Reasons to Buy the Report: - Market Penetration: Comprehensive information on product portfolios of top players in the pharmaceutical membrane filtration market. The report analyzes the pharmaceutical membrane filtration market by application across geographies. - Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the pharmaceutical membrane filtration market. - Market Diversification: Exhaustive information about new technologies, applications, and emerging geographies in the pharmaceutical membrane filtration market. - Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the pharmaceutical membrane filtration market. Key Topics Covered: Introduction Executive Summary Market Dynamics Pharmaceutical Membrane Filtration Market - By Technology Pharmaceutical Membrane Filtration Market - By Application Pharmaceutical Membrane Filtration Market - By Geography Competitive Landscape Company Profiles List of Tables Companies Mentioned - 3M - Alfa Laval - GE - GEA Group - Graver Technologies - Koch Membrane Systems - MECO - Merck Millipore - Novasep - Pall Corporation - Sartorius Stedim Biotech - Spectrum Laboratories For more information visit http://www.researchandmarkets.com/research/kf...maceutical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Markets for Bioseparations for Biopharmaceutical Manufacturing to Jump to $6 Billion by 2018
M2 - Tue Aug 13, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pq64s6/bioseparation) has announced the addition of the "Bioseparation Systems for Global Biopharmaceutical Markets" report to their offering. 72 1024x768 Normal 0 false false false This new report, "Global Markets for Bioseparations for Biopharmaceutical Manufacturing," cites that the global market for bioseparations for biopharmaceutical manufacturing will grow to $6 billion by 2018. While North America and Europe will continue to account for a significant share of revenue, the emerging countries of China, India, Brazil and Russia are rapidly increasing share, growing at a CAGR of 22%. The demand for single use products is increasing and fueling growth of the global bioseparations market. Blockbuster biologics are going off patent, leaving the market open for developing and manufacturing low cost biosimilars. The Asian countries of India, Singapore, South Korea and China are fast becoming biomanufacturing hubs, producing biosimilars for their own large populations and for Southeast Asia. bioseparations market. Membranes/filters will contribute $1.4 billion, followed by centrifuges ($400 million). The "Global Markets for Bioseparations for Biopharmaceutical Manufacturing" report covers: Normal 0 false false false MicrosoftInternetExplorer4 The "Global Markets for Bioseparations for Biopharmaceutical Manufacturing" report examines companies manufacturing biopharmaceutical manufacturing equipment and supplies in the world. Companies covered include: - Agilent Technologies - Alfa Wassermann Separation Technologies - Applied Biosystems Corporation (Life Technologies) - Asahi Kasei - Bio-Rad Laboratories - Carr Centritech - Celeros - DSM Biologics - Dow Chemical Company - Flottweg Separations Technology - G-Con Manufacturing - GE Healthcare Life Sciences - GEA Westfalia Separator Group - Hitachi Koki Co LTD - Knauer - Kronlab (YMC Europe) - Life Technologies - M Cuno - Meissner Filtration Products, Inc - Merck Millipore - Novasep Life Sciences Manufacturing Solutions - Novavax - NuSep Holdings Ltd - Pall Corporation - ProMetic Life Sciences Inc - Sartorius Stedim Biotech - SciLog - Spectrum Laboratories - Tarpon Biosystems - Tosoh Bioscience - US Filter Control Systems, Inc - Waters Corporation For more information visit http://www.researchandmarkets.com/research/pq...separation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

IV Fluid Transfer Devices Report - Products, Players, Markets and Opportunities
M2 - Wed Jun 26, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fnpmtc/iv_fluid_transfer) has announced the addition of the "IV Fluid Transfer Devices Products, Players, Markets and Opportunities" report to their offering. Intravenous drug administration is one of the most common therapeutic procedures that patients in a hospital setting are likely to receive. Yet the lack of standardization among the various components, elements and steps that a caregiver must navigate to successfully execute a drug intravenously have - according to several recent studies - contributed to medication errors and risks to patient safety. IV drug administration was once provided to patients only in clinical settings. However, technology developments and a greater emphasis on cost containment over the last 30 years have prompted a shift to providing this therapy in alternate settings, including the home. Highlights: - Analyzes the global market for IV fluid transfer devices market segments, and assesses the probable market

ProMetic and Sartorius Stedim Biotech ("SSB" Join Forces to Promote Novel Turnkey Solution for Producing Plasma-Derived Therapeutics
Marketwire - Tue Apr 30, 4:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation" announced today the expansion of its existing strategic collaboration with Sartorius Stedim Biotech ("SSB" to include a contribution of equipment to ProMetic's plasma purification facility as well as an agreement for the co-commercialization of PPPS(TM) on a global basis.

Sartorius Stedim Biotech: Fact Sheet on New Reporting Format
Business Wire - Mon Apr 15, 1:32PM CDT
From the first quarter of 2013 onwards, Sartorius Stedim Biotech (Paris IM) will adopt a few slight changes to its reporting in order to follow established international reporting practice and thus to provide financial data in the best comparable manner. Relevant changes relate to amortization as well as to other taxes, which are now shown under functional expenses. Moreover, going forward underlying EBITDA will be used as the key performance indicator instead of underlying EBITA, which has been used so far. However, these changes to cost allocations do not influence the net result of the group. This fact sheet translates Sartorius Stedim Biotech's business figures for 2012 as well as its earnings guidance for 2013 according to these changes.

Sartorius Stedim Biotech Expands Portfolio by Adding Cell Culture Media
Business Wire - Wed Dec 19, 12:00AM CST
--Long-term collaboration, supply and distribution agreement with Swiss-based life science group Lonza




Scroll down for more posts ▼

Top 10 Most Recent News Articles

SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 11

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 43

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading
Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 16

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 234

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 114

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Microsoft-Intel Azure Pact Puts Systems Work First

Updated Category News Views 18

Azure’s next bottleneck may be the plumbing between chips, not the chips alone. Microsoft and Intel announced on Nov. 18, 2026, a long-term expansion of their already ancient partnership aimed at shaping select pieces of Azure infrastructure for cloud and AI demand. That sounds dry, because infrastructure announcements usually do. But this one deserves a closer look: it...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 134

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 65

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading

Top 5 Most Recently Viewed Articles

Symbotic Inc. Faces Legal Challenges Amid Financial Irregularities

Updated Category News Views 138

Symbotic Inc. Under Investigation for Securities Violations There has been a significant development for investors of Symbotic Inc. As concerns about the Company’s financial practices have arisen, the Schall Law Firm has initiated an investigation. This effort is aimed at ensuring shareholders are informed and protected amid allegations of misleading statements related...

Continue Reading
Turning Point Brands: Growth Opportunities Ahead with New Rating

Updated Category News Views 103

Turning Point Brands Gets a Positive Buy Rating Recently, Turning Point Brands (NYSE: TPB) earned a favorable Buy rating from Roth/MKM, along with a price target set at $50. This company is known for its wide range of consumer brands in the nicotine, tobacco, and cannabis markets, particularly recognized for its popular rolling papers and moist snuff products. Growth in...

Continue Reading
NeuroSense Therapeutics Celebrates Key Manufacturing Milestone

Updated Category News Views 232

NeuroSense Therapeutics Achieves Commercial Manufacturing Scale-Up NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a pioneering biotechnology firm dedicated to developing innovative treatments for severe neurodegenerative diseases, has announced a major milestone in its commercial journey. The company has successfully scaled up its production of PrimeC, preparing for...

Continue Reading
Discover the Potential of Azapeptides in Peptide Stability

Updated Category News Views 179

Unveiling the Future of Peptide Stability with Azapeptide Synthesis In this informative webinar, participants will discover how strategies involving azapeptides can significantly enhance the stability of peptides and improve workflows related to synthesis. Attendees will delve into techniques for incorporating aza-amino acids within peptides that utilize traditional amino...

Continue Reading
Ascent Solar Technologies Faces Major Challenges in Market

Updated Category News Views 118

Ascent Solar Technologies Hits 52-Week Low Ascent Solar Technologies, recognized for its cutting-edge thin-film photovoltaic modules, is currently going through a challenging period. The company's stock has reached a 52-week low of $2.32, reflecting an astonishing nearly 99.6% decline over the past year. This drastic drop underscores the significant hurdles the company...

Continue Reading